IXICO announces new contract with leading biopharmaceutical company

Digital technologies company IXICO has today announced a new contract with an undisclosed leading biopharmaceutical company to support the use of wrist-worn activity sensors in a late stage trial for a psychiatric disorder for £0.75m over a two- year term.

Commencing in November, IXICO said the contract would be the company's second commercial agreement involving wearable biosensors, following the announcement of another contract on 4 October 2017 to measure sleep disturbance from biosensor data collected from people with a neurological disorder.

The company aims to utilise its biosensor capabilities, alongside its artificial intelligence data analytics algorithms to measure sleep, day-time napping and overall daily activity levels, as "better measurement of day and night time sleep" becomes of increasing interest in clinical research as well as clinical practice.

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to announce this first contract with a new biopharma customer, providing our wearable biosensor capabilities and technology to support this late phase clinical trial. This study is focused on monitoring the treatment of patients with a serious psychiatric disorder, further supporting our view that wearable biosensors have broad utility in clinical research in many therapeutic areas. These two contracts represent an excellent opportunity for IXICO to provide new, innovative digital technologies as part of our commercially led growth strategy."